Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal group A, C, W-135 and Y conjugate vaccine + hepatitis A (inactivated) and hepatitis B (recombinant) vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Nimenrix + Twinrix refers to the co-administration of two distinct vaccine products developed by GSK: Nimenrix, a quadrivalent meningococcal conjugate vaccine, and Twinrix, a combined hepatitis A and hepatitis B vaccine. Nimenrix provides active immunization against Neisseria meningitidis serogroups A, C, W-135, and Y by utilizing capsular polysaccharides conjugated to a tetanus toxoid carrier protein. Twinrix contains inactivated hepatitis A virus (HM175 strain) and recombinant hepatitis B surface antigen (HBsAg) produced in yeast cells, adsorbed onto aluminum salts to enhance the immune response. This combination regimen is frequently employed in clinical practice for travelers or adolescents who require simultaneous protection against invasive meningococcal disease and hepatitis A and B infections. Clinical studies have demonstrated that the co-administration of these vaccines at separate injection sites is safe and does not interfere with the immunogenicity of either component.
- Other names
- MenACWY-TT + HepA-HepBmeningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine + hepatitis A (inactivated) and hepatitis B (adsorbed) vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Group Y CPS (Neisseria meningitidis group Y capsular polysaccharide)Hepatitis A virus capsid proteinNeisseria meningitidis group C capsular polysaccharideMenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)HBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on meningococcal group A, C, W-135 and Y conjugate vaccine + hepatitis A (inactivated) and hepatitis B (recombinant) vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal group A, C, W-135 and Y conjugate vaccine + hepatitis A (inactivated) and hepatitis B (recombinant) vaccine.